The US Army Medical Research Institute of Infectious Diseases (USAMRIID) announced that, for the first time, the US Food and Drug Administration (FDA) has provided formal regulatory agreement for use of an animal model to support development of a drug candidate, remdesivir, for treating deadly Ebola virus infections.
The Pandemic Response Box contains 400 diverse drug-like molecules active against bacteria, viruses or fungi.
Medicines for Malaria Venture (MMV) and the Drugs for Neglected Diseases initiative (DNDi) have launched the Pandemic Response Box to provide researchers with free access to 400 diverse compounds to accelerate the discovery of new treatments for life-threatening pandemic diseases.
The aim of the conference is to harness cross-disciplinary and cross-disease learning to accelerate drug discovery and reduce drug candidate attrition rates for infectious diseases affecting low and middle income countries. Conference attendees will take home new ideas and technologies which have been demonstrated to work; applying them to diseases where challenges to drug discovery are hampering progress.
Coupled with a novel web-based bioinformatics pipeline, the researchers hope the library, which will not only provide information to help classify bacteria but also will help identify the antibiotics an individual species might produce, will remove years of work from the drug discovery process.
By operating in a regulatory blind spot, DIYers could upset the status quo for drug production.
There is little financial incentive for pharmaceutical companies to bring vaccines to the market.
The US Food and Drug Administration (FDA) announced the addition of Lassa fever, chikungunya virus disease, rabies and cryptococcal meningitis to the list of tropical diseases.
Machine-learning model could help chemists make molecules with higher potencies, much more quickly.